BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

JSKN003: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Shanghai JMT-Bio Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-30 est.P3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06751485 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian CancerOvarian Cancer; Primary Peritoneal; Fallopian Tube Cancersnot yet recruiting430

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-13 est.P3Shanghai JMT-Bio Inc.NCT06846437 JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast CancerUnrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participantsrecruiting228
2026-07-30 est.P1/P2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT05744427 Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting725

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.